MONTPELLIER, France

法国蒙彼利埃

,

，

July 8, 2026

2026年7月8日

/PRNewswire/ -- Tsingke, a provider of integrated life science research solutions, participated in the Antibody Industrial Symposium (AIS) 2026, one of Europe's leading conferences dedicated to therapeutic antibodies and biotherapeutics. At the event, the company presented its latest advances in AI-assisted therapeutic antibody discovery and showcased its comprehensive antibody development platform at Booth #44..

/美通社/ -- 一体化生命科学研究解决方案提供商擎科参加了2026年抗体产业研讨会（AIS），这是欧洲专注于治疗性抗体和生物疗法的领先会议之一。在活动中，该公司展示了其在人工智能辅助治疗性抗体发现方面的最新进展，并在44号展位展示了其全面的抗体开发平台。

AI-Enabled Discovery of Highly Selective CLDN18.2 Antibodies

人工智能赋能的高选择性CLDN18.2抗体发现

Continue Reading

继续阅读

Tsingke details its AI-enabled workflow for highly selective CLDN18.2 antibody discovery and reduced cross-reactivity during a scientific presentation at the Antibody Industrial Symposium (AIS) 2026.

在2026年抗体产业研讨会（AIS）上，擎科详细阐述了其利用人工智能技术实现高选择性CLDN18.2抗体发现并降低交叉反应性的工作流程。

As part of the scientific program, Tsingke presented an AI-enabled workflow for discovering therapeutic antibodies targeting Claudin 18.2 (CLDN18.2), an emerging target for gastric cancer and other solid tumors.

作为科学计划的一部分，擎科展示了一种人工智能赋能的工作流程，用于发现靶向Claudin 18.2（CLDN18.2）的治疗性抗体。CLDN18.2是胃癌及其他实体瘤的一个新兴靶点。

The presentation demonstrated how AI-assisted sequence analysis and a proprietary screening strategy improve target specificity by reducing potential cross-reactivity with the closely related CLDN18.1 protein, a longstanding challenge in CLDN18.2 antibody development.

该演示展示了人工智能辅助序列分析和专有筛选策略如何通过减少与密切相关的CLDN18.1蛋白的潜在交叉反应性来提高靶点特异性，这是CLDN18.2抗体开发中长期存在的挑战。

The resulting antibody candidates showed strong specificity and favorable developability, highlighting the potential of integrating AI with experimental validation to accelerate therapeutic antibody and antibody-drug conjugate (ADC) development.

所得抗体候选分子表现出强特异性和良好的可开发性，凸显了将人工智能与实验验证相结合以加速治疗性抗体及抗体药物偶联物（ADC）开发的潜力。

End-to-End Antibody Development Capabilities

端到端抗体开发能力

In addition to its scientific presentation, Tsingke showcased its integrated antibody development platform, covering multiple stages of biologics discovery and development, including:

除了科学展示外，擎科还展示了其一体化抗体开发平台，涵盖生物制剂发现和开发的多个阶段，包括：

Antibody Discovery

抗体发现

using hybridoma, single B-cell, and phage display technologies for the identification of high-affinity and highly specific antibodies.

利用杂交瘤、单B细胞和噬菌体展示技术鉴定高亲和力且高特异性的抗体。

Antibody Engineering

抗体工程

including antibody humanization, affinity maturation, and synthetic antibody library construction to accelerate therapeutic antibody optimization.

包括抗体人源化、亲和力成熟以及合成抗体文库构建，以加速治疗性抗体的优化。

Protein Expression

蛋白质表达

supported by six expression systems and a rapid gene-to-protein workflow for applications including monoclonal antibodies, ADCs, AOCs, and in vitro diagnostics (IVD).

由六种表达系统和快速基因到蛋白质的工作流程支持，适用于单克隆抗体、ADC、AOC和体外诊断（IVD）等应用。

'AIS 2026 provided an excellent opportunity to share our latest work in AI-enabled antibody discovery and connect with researchers across the antibody community,' said

“AIS 2026 为分享我们在人工智能赋能的抗体发现领域的最新成果，并与抗体研究领域的广大科研人员建立联系，提供了绝佳的机会。”

Chuanting Tan, Senior R&D Engineer at Tsingke

谭传庭，清科高级研发工程师

. 'As therapeutic antibody development becomes increasingly complex, integrating computational approaches with experimental validation can help researchers identify and optimize promising candidates more efficiently. We will continue to enhance our discovery and development capabilities to support innovation in biologics research.'.

“随着治疗性抗体开发日益复杂，将计算方法与实验验证相结合，可以帮助研究人员更高效地识别和优化有前景的候选分子。我们将持续提升我们的发现与开发能力，以支持生物药研究的创新。”

Building on these efforts, Tsingke will continue expanding its AI-enabled discovery platform and integrated biologics capabilities to help researchers accelerate projects from early target discovery through protein expression and characterization.

在此基础上，擎科将继续拓展其人工智能驱动的发现平台及一体化生物药研发能力，助力研究人员加速从早期靶点发现到蛋白表达与表征的项目进程。

About Tsingke

关于青科

Tsingke Biotech

擎科生物

is a leading innovator in synthetic biology, with a mission to build 'the world's great gene factory.' Combining proprietary reagents, consumables, and synthesis equipment with AI-driven molecular manufacturing technologies, Tsingke Biotech provides efficient and high-quality Tsynth® gene synthesis services.

擎科生物是合成生物学领域的领先创新者，致力于构建“世界级的基因工厂”。通过将专有试剂、耗材和合成设备与人工智能驱动的分子制造技术相结合，擎科生物提供高效且高质量的Tsynth®基因合成服务。

Its work supports industries ranging from biopharma to agriculture, food, and environmental sciences..

其工作支持从生物制药到农业、食品和环境科学等多个行业。

For news and updates, follow Tsingke Biotech on

如需获取新闻和最新动态，请关注清科生物在

LinkedIn

领英

.

。

Contact:

联系方式：

[email protected]

[email protected]

SOURCE Beijing Tsingke Biotech Co., Ltd.

来源：北京擎科生物科技有限公司

21

二十一

%

%

more press release views with

更多新闻稿浏览量，通过

Request a Demo

申请演示